Open Access
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03102
Number of page(s) 7
Section Environmental Sustainable Development and Industrial Transformation
Published online 09 September 2021
  1. Hu L, Liang J, Jin SY, Han YJ, Lu J, Tu Y. [Progress of researches on mechanisms of acupuncture underlying improvement of depression in the past five years]. Zhen Ci Yan Jiu. 2013 Jun;38(3):253-8. Chinese. [PubMed] [Google Scholar]
  2. Glover GR. Unrecognised depression in general practice. Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):140. [PubMed] [Google Scholar]
  3. de Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019). Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review. Epidemiology and psychiatric sciences, 28(5), 544–562. [PubMed] [Google Scholar]
  4. Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., Espil, F. M., Pannu, J., Xiao, X., Duvio, D., Solvason, H. B., Hawkins, J., Guerra, A., Jo, B., Raj, K. S., Phillips, A. L., … Williams, N. R. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. The American journal of psychiatry, 177(8), 716–726. [PubMed] [Google Scholar]
  5. George, M. S., Wassermann, E. M., Williams, W. A., Callahan, A., Ketter, T. A., Basser, P., Hallett, M., & Post, R. M. (1995). Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport, 6(14), 1853–1856. [PubMed] [Google Scholar]
  6. Pascual-Leone A, Rubio B, Pallardó F, Catalá MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27; 348(9022):233-7. [PubMed] [Google Scholar]
  7. Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas. 2013;25(2):191-2. [PubMed] [Google Scholar]
  8. Hirschfeld RM. Major depression, dysthymia and depressive personality disorder. Br J Psychiatry Suppl. 1994 Dec; (26):23-30. [Google Scholar]
  9. Albert PR. Light up your life: optogenetics for depression? J Psychiatry Neurosci. 2014 Jan; 39(1):3-5. [PubMed] [Google Scholar]
  10. Evans S, Alkan E, Bhangoo JK, Tenenbaum H, Ng-Knight T. Effects of the COVID-19 lockdown on mental health, wellbeing, sleep, and alcohol use in a UK student sample. Psychiatry Res. 2021 Apr; 298:113819. [PubMed] [Google Scholar]
  11. Rogers D, Pies R. General medical with depression drugs associated. Psychiatry (Edgmont). 2008 Dec; 5(12):28-41. [PubMed] [Google Scholar]
  12. Geisner IM, Mallett K, Varvil-Weld L, Ackerman S, Trager BM, Turrisi R. An examination of heavy drinking, depressed mood, drinking related constructs, and consequences among high-risk college students using a person-centered approach. Addict Behav. 2018 Mar; 78:22-29. [PubMed] [Google Scholar]
  13. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7. [PubMed] [Google Scholar]
  14. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61 Suppl 6:4-6. [PubMed] [Google Scholar]
  15. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87. [PubMed] [Google Scholar]
  16. Godlewska BR, Browning M, Norbury R, Cowen PJ, Harmer CJ. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Transl Psychiatry. 2016 Nov 22;6(11):e957. [PubMed] [Google Scholar]
  17. Sánchez C, Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl). 1997 Feb; 129(3):197-205. [PubMed] [Google Scholar]
  18. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003 Apr;160(4):790-2. [CrossRef] [PubMed] [Google Scholar]
  19. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983 May;16(1):87-101. [CrossRef] [PubMed] [Google Scholar]
  20. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, Germain JM, Pitrosky B. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008 Jul;23(4):188-97. [PubMed] [Google Scholar]
  21. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006 Apr;7(4):295-309. [PubMed] [Google Scholar]
  22. Zhang A, Borhneimer LA, Weaver A, Franklin C, Hai AH, Guz S, Shen L. Cognitive behavioral therapy for primary care depression and anxiety: a secondary meta-analytic review using robust variance estimation in meta-regression. J Behav Med. 2019 Dec;42(6):1117-1141. [PubMed] [Google Scholar]
  23. Weissman MM. Interpersonal Psychotherapy: History and Future. Am J Psychother. 2020 Mar 1;73(1):3-7. [PubMed] [Google Scholar]
  24. Scheff TJ. Shame and community: social components in depression. Psychiatry. 2001 Fall; 64(3):212-24. [PubMed] [Google Scholar]
  25. Beatty L, Binnion C. A Systematic Review of Predictors of, and Reasons for, Adherence to Online Psychological Interventions. Int J Behav Med. 2016 Dec; 23(6):776-794. [PubMed] [Google Scholar]
  26. Lobo MK, Nestler EJ, Covington HE 3rd. Potential utility of optogenetics in the study of depression. Biol Psychiatry. 2012 Jun 15;71(12):1068-74. doi: 10.1016/j.biopsych.2011.12.026. Epub 2012 Feb 8. PMID: 22322104; PMCID: PMC3738208. [PubMed] [Google Scholar]
  27. Golden SA, Covington HE 3rd, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. Nat Protoc. 2011 Jul 21;6(8):1183-91. [PubMed] [Google Scholar]
  28. Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. [PubMed] [Google Scholar]
  29. Lawson McLean A. Publication trends in transcranial magnetic stimulation: a 30-year panorama. Brain Stimul. 2019 May-Jun;12(3):619-627. [PubMed] [Google Scholar]
  30. Averill, Lynnette A et al. “Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.” Advances in pharmacology (San Diego, Calif.) vol. 89 (2020): 163-194. [Google Scholar]
  31. Adamczyk, A.K., Zawadzki, P. The Memory-Modifying Potential of Optogenetics and the Need for Neuroethics. Nanoethics 14, 207–225 (2020). [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.